New dietary ingredient notifications
This article was originally published in The Tan Sheet
Executive Summary
FDA should issue a guidance to explain when new dietary ingredient notifications are necessary, as well as the type of information they should include, NNFA says in May 9 letter to the agency. Guidance should establish "whether, and under what conditions, a dietary ingredient that is a component of food (i.e. lycopene in tomatoes) would be exempt" from notification, as well as the quantity, quality of information required to satisfy the "history of use or other evidence of safety" standard. NNFA's comments respond to March 19 FDA notice requesting public feedback on premarket notification process for new dietary ingredients...
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.